CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) VP David Foehr sold 987 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $18.00, for a total value of $17,766.00. Following the transaction, the vice president owned 38,613 shares of the company’s stock, valued at approximately $695,034. This represents a 2.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
David Foehr also recently made the following trade(s):
- On Friday, May 22nd, David Foehr sold 862 shares of CeriBell stock. The shares were sold at an average price of $18.80, for a total value of $16,205.60.
- On Tuesday, March 3rd, David Foehr sold 4,560 shares of CeriBell stock. The shares were sold at an average price of $17.80, for a total transaction of $81,168.00.
CeriBell Stock Up 0.2%
Shares of CBLL traded up $0.03 during trading hours on Tuesday, hitting $18.80. The company had a trading volume of 187,155 shares, compared to its average volume of 322,889. The stock has a market capitalization of $713.27 million, a price-to-earnings ratio of -11.53 and a beta of 0.99. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44. CeriBell, Inc. has a 52-week low of $10.85 and a 52-week high of $24.33. The firm has a fifty day moving average price of $19.08 and a 200-day moving average price of $19.19.
Analysts Set New Price Targets
A number of research firms recently commented on CBLL. BTIG Research reissued a “buy” rating and issued a $30.00 price target on shares of CeriBell in a report on Wednesday, January 28th. Canaccord Genuity Group dropped their price objective on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. Finally, Weiss Ratings cut CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $22.20.
View Our Latest Analysis on CeriBell
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Strs Ohio bought a new position in shares of CeriBell during the first quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd grew its stake in shares of CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after acquiring an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of CeriBell in the third quarter worth $33,000. CWM LLC lifted its position in CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after acquiring an additional 1,697 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after acquiring an additional 1,801 shares during the last quarter.
CeriBell Company Profile
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
Featured Articles
- Five stocks we like better than CeriBell
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
